MAP2K1 and neoplasm: To examine the effect of MAP2K1 and DDR2 inhibition on tumor growth, mice bearing MFC tumors were injected with MAP2K1-targeting trametinib or DDR2-targeting sitravatinib (supplemental Fig. S3).